What is Vera Therapeutics's G&A?

Vera Therapeutics (VERA) reported G&A of $39.12M in Q1 2026.

How has Vera Therapeutics's G&A changed year-over-year?

Vera Therapeutics's G&A increased by 145.8% year-over-year, from $15.92M to $39.12M.

What is the long-term trend for Vera Therapeutics's G&A?

Over 4 years (2021 to 2025), Vera Therapeutics's G&A has grown at a 70.3% compound annual growth rate (CAGR), from $11.92M to $100.22M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Vera Therapeutics VERA G&A

G&A at other companies

Immunovant, Inc.IMVT

$17.27M-14.4%

Alumis Inc.ALMS

$18.61M-16.5%

Adaptive BiotechnologiesADPT

$20.98M+20.6%

Kodiak Sciences IncKOD

$11.23M-27.2%

Dianthus TherapeuticsDNTH

$12.47M+69.9%

Kymera TherapeuticsKYMR

$20.36M+25.1%

Other financials

Income statement

See full

Operating income-$125.1M-119%

Net income-$121.0M-134%

EPS (diluted)-$1.69-109%

Balance sheet

See full

Cash & equivalents$114.4M+108%

Total debt$75.0M+37.8%

Total equity$499.7M-6.6%

Total assets$621.7M+1.9%

Cash flow

See full

Operating cash flow-$106.5M-95.8%

CapEx$23.0K-87.7%

Free cash flow-$106.5M-95.1%

Valuation

See full

Market cap$2.74B+87.5%

Enterprise value$2.7B+85.0%

Returns & leverage

See full

Return on equity-71.3%+296pp

Debt / equity0.2×0.0×

Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vera Therapeutics's G&A?: Vera Therapeutics (VERA) reported G&A of $39.12M in Q1 2026.
How has Vera Therapeutics's G&A changed year-over-year?: Vera Therapeutics's G&A increased by 145.8% year-over-year, from $15.92M to $39.12M.
What is the long-term trend for Vera Therapeutics's G&A?: Over 4 years (2021 to 2025), Vera Therapeutics's G&A has grown at a 70.3% compound annual growth rate (CAGR), from $11.92M to $100.22M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.